Urogenital atrophy is a common problem for the growing number of women with a history of breast cancer. Whether the condition is a result of menopause, cancer treatment, or both, complaints that include vaginal dryness, itchiness, and dyspareunia can diminish quality of life. This case reviews management of urogenital atrophy in a woman whose oncologist switched her from tamoxifen to an aromatase inhibitor.
Primary care physicians and physician assistants
After taking part in this educational activity, participants should be better able to:
- Identify signs and symptoms of genital atrophy associated with menopause
- Develop an individually appropriate treatment plan for patients with menopausal genital atrophy and a history of breast cancer
AMA PRA Category 1 Credit(s)TM
This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through joint sponsorship of the Colorado Foundation for Medical Care, Office of Continuing Education and Haymarket Medical Education. CFMC is accredited by the ACCME to provide continuing medical education for physicians.
Colorado Foundation for Medical Care designates this enduring material internet activity for a maximum of 0.75 AMA PRA Category 1 Credit™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Andrew Kaunitz, MD
Professor and Associate Chairman, Department of Obstetrics and Gynecology
University of Florida College of Medicine
Disclosure of Conflicts of Interest
Colorado Foundation for Medical Care ensures balance, independence, objectivity, and scientific rigor in all our educational activities. In accordance with this policy, CFMC identifies conflicts of interest with its instructors, content managers, and other individuals who are in a position to control the content of an activity. Conflicts are resolved by CFMC to ensure that all scientific research referred to, reported, or used in a CME activity conforms to the generally accepted standards of experimental design, data collection, and analysis. CFMC is committed to providing its learners with high-quality CME activities that promote improvements or quality in health care and not the business interest of a commercial interest.
Andrew Kaunitz, MD, is a consultant for Bayer HealthCare Pharmaceuticals, Merck Inc., Noven Pharmaceuticals, and Teva Pharmaceuticals. He also receives research funding (disbursed to the University of Florida Research Foundation) from Bayer HealthCare Pharmaceuticals, Endoceutics, Noven Pharmaceuticals, and Teva Pharmaceuticals.
All other members of the faculty and planning team have nothing to disclose nor do they have any vested interests or affiliations. It is the policy of Haymarket Medical Education and Colorado Foundation for Medical Care (CFMC) that the faculty discloses real or apparent conflicts of interest relating to the topics of the educational activity.
Disclosure of Unlabeled Use
This educational activity may contain discussion of approved and/or investigational uses of agents that are not indicated by the FDA. CFMC and Haymarket Medical Education do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of CFMC and HME. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Learners are required to adhere to the privacy and confidentiality policy as it relates to the CME activities provided on the Internet. Please see CFMC’s policy at yourcesource.com/privacy.htm.
Copyright © 2012 (Haymarket Medical Education). All rights reserved. This material may not be reproduced, displayed, modified, or distributed without the express prior written permission of the copyright holder.
This program is jointly sponsored by Colorado Foundation for Medical Care and Haymarket Medical Education.
If you have any questions relating to the accreditation of this activity, please contact Craig Mattingly at CFMC via email at email@example.com.
Questions pertaining to the content, programming, or system issues please contact myCME Web Support at myCME.Support@haymarketmedical.com.
There is no commercial support for this educational activity.
To obtain credit, a score of 70% or better is required. This CME is offered at no cost to participants. Please proceed with the activity until you have successfully completed this program, answered all test questions, completed the posttest survey, and have received your digital copy of your credit certificate. Your online certificate will be saved on myCME.com within your Profile/Exam History, which you can then access at any time.
WINDOWS PC SYSTEM REQUIREMENTS:
266-MHz Pentium II; Windows 98 or higher; 64 MB RAM; 800 x 600 screen resolution
set for “High Color (16-Bit)”; Macromedia Flash Player 6 or higher.
MACINTOSH® SYSTEM REQUIREMENTS:
Power Mac g3 at 300 MHz; System 8.5 or higher (excluding Mac OSX); 96 MB RAM; 20
MB minimum hard disk space available; 800 x 600 screen resolution set to “Thousands
of Colors”; Macromedia Flash Player 6 or higher.